A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis.
Wagner
J A
JA
Department of Molecular Pharmacology, Stanford University School of Medicine, CA 94305-5332, USA.
Moran
M L
ML
Messner
A H
AH
Daifuku
R
R
Conrad
C K
CK
Reynolds
T
T
Guggino
W B
WB
Moss
R B
RB
Carter
B J
BJ
Wine
J J
JJ
Flotte
T R
TR
Gardner
P
P
D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D002985:Clinical Protocols; D003550:Cystic Fibrosis / Q000150:complications / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics* / Q000627:therapeutic use*; D000229:Dependovirus / Q000235:genetics; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D008875:Middle Aged; D012852:Sinusitis / Q000150:complications / Q000628:therapy*
C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator